The Food and Drug Administration granted marketing approval to AstraZeneca’s gout medicine Zurampic. Zurampic was approved as combination therapy with a xanthine oxidase inhibitors (XOIs) for the treatment of hyperuricemia — an excess of uric acid in the blood — associated with gout in patients who have responded to XOIs alone.
{iframe}http://www.bizjournals.com/philadelphia/morning_roundup/2015/12/fda-approves-astrazeneca-gout-medicine.html?ana=e_phil_rdup&s=newsletter&ed=2015-12-23&u=wjGEy67ABoSnsLErlc5ry0j5hx3&t=1450900282{/iframe}